Although well-characterized in the lung, the role of platelet-activating factor (PAF) Haemophilus influenzae, indicating a special role for PAF in pneumococcal disease. Antibodies directed at phosphorylcholine, a unique, shared determinant of bioactivity of PAF and pneumococcal cell wall, obviated the inflammatory potential of both agents. However, no evidence for a direct PAF-like activity of pneumococcal cell wall components was detected in vitro by bioassay using platelets or neutrophils. It is concluded that PAF can induce inflammation in the subarachnoid space. In brain, PAF effects appear to be mediated through CD-18-dependent events, while in lung, PAF effects independent of CD-18 are also evident. At both sites, PAF is of particular clinical importance during inflammation induced by pneumococci apparently due to a unique proinflammatory relationship between the pneumococcal cell wall teichoic acid and PAF. (J. Clin.
Introduction
Platelet activating factor (PAF)l is a mediator ofinflammation produced by macrophages, neutrophils, platelets, and endothelial cells in response to injury (1, 2) . PAF induces cellular activation by binding to a receptor that is a member of the super-family of G proteins (3) . The sequelae of PAF-receptor interactions are varied but have been most clearly defined in the lung. They include bronchoconstriction, increased vascularpermeability with protein exudation, and platelet aggregation. PAF has been implicated in the release of cytokines such as tumor necrosis factor (4) and putatively plays a role in the pathophysiology of anaphylaxis, shock, and adult respiratory distress syndrome (2, 5) . We sought to define the role of this potent mediator in the inflammatory response elicited during bacterial meningitis.
It is widely recognized that invasive pneumococcal infection is characterized by particularly intense inflammation. In pneumococcal meningitis this leads to the highest rates ofmortality and morbidity of common meningeal pathogens (6) . Studies of pneumonia also indicate that pneumococcal infection triggers leukocyte recruitment mechanisms that are more complex than those seen with Gram-negative infection (7) . We have demonstrated that inflammation during pneumococcal infection of both the subarachnoid space and the lung is induced in large part by the pneumococcal cell wall (8-10) and thus hypothesize that special features ofthe pneumococcal cell wall confer its enhanced inflammatory potential.
Pneumococcal cell wall is a complex macromolecule composed of two major polymers: a peptidoglycan and a teichoic acid ofunusually complex structure that contains a constituent unique among pathogens: phosphorylcholine (11) . In addition to the wall-bound teichoic acid, pneumococci also harbor a lipid-linked form of the teichoic acid, the lipoteichoic acid or Forssman antigen (12) (Fig. 1) . Although many pneumococcal cell wall subcomponents are inflammatory, teichoic acidcontaining cell wall fragments have the highest inflammatory activity: these components trigger the alternative pathway of complement activation in vitro (13) , induce leukocytosis and increased vascular permeability in models of meningitis and pneumonia (8) (9) (10) , and, at concentrations 100-fold lower than endotoxin, induce secretion of IL-1 from macrophages (14) and induce procoagulant activity on endothelial cells (15) . These findings suggest that the pneumococcal teichoic acid and lipoteichoic acid have unusual inflammatory potential. This is further supported by the findings that neutralization of the inflammatory activity of the teichoic acid and lipoteichoic acid by antiphosphorylcholine antibodies or C-reactive protein is protective in murine models of sepsis (16, 17) .
Phosphorylcholine is not found in the cell walls of pathogens other than the pneumococcus and this moiety is a critical determinant ofthe inflammatory activity ofthe pneumococcal AcO-c Platelet Activating Factor CH20- P-OCH2CH2N   -I~I   CH20-P-OCH2CH2N-OCH2  CH3  CH20H I teichoic and lipoteichoic acids (8, 9, 14) . Phosphorylcholine is also a critical determinant ofthe biological activity of PAF (1) (Fig. 1 ). Like the pneumococcal teichoic and lipoteichoic acids, PAF reacts with the acute phase reactant, C-reactive protein, but rather than neutralizing its bioactivity, this complex enhances PAF-induced platelet aggregation (18) . These relationships between the phosphorylcholine-dependent inflammatory activities ofpneumococcal cell wall and those of PAF suggested the possibility that PAF might play a special role inpneumococcal disease. The aims of our study were threefold: (a) to determine the ability of PAF to induce inflammation and altered physiology in the subarachnoid space and the lung; (b) to determine if PAF is activated during pneumococcal meningitis or pneumonia; and finally (c) to assess if the pneumococcal teichoic acid or lipoteichoic acid can act as agonists at the PAF receptor.
Methods
Preparation of platelet-activating factor, bacterial components, and antibodies. PAF (I-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine; Sigma Chemical Co., St. Louis, MO) was diluted in chloroform/methanol (9:1 ) and stored at -20'C. Immediately before use, aliquots were removed and dried under a stream of air. PAF was rediluted in 0.2 ml of saline, sonicated for 2 min, and 100 Ag was instilled in 0.2 ml of saline intracisternally or intratracheally.
Unencapsulated Streptococcus pneumoniae strain R6 or Haemophilus influenzae type b strain Eagan were grown to mid-logarithmic phase as described (6, 19) , washed, and resuspended in pyrogen-free saline. I0O cell equivalents were administered intracisternally or intratracheally in a volume of 0.2 ml. In some experiments, pneumococci
were boiled for 20 min in growth medium before introduction into the animal models; this preparation of killed cells is known to induce a highly reproducible inflammatory response similar to natural disease. Pneumococcal cell wall was prepared according to an established protocol from strain R6 (8 (21, 22) , was prepared as a 2-mg/ml (5-mM) solution in dimethylsulfoxide. Immediately before use, 50-,Ml aliquots were diluted into 0.5 ml isotonic saline preheated to 550C, and 100 Ml was injected intravenously or intracisternally per rabbit. This dose of 10 Mg/kg (25 MM/kg) was previously shown to be at least 1,000-fold greater than the ED5o for inhibition of PAF-induced effects on rabbit platelets and neutrophils in vitro and equal to the ED50 to inhibit PAF-induced bronchoconstriction in guinea pigs (22) . In pilot experiments using the meningitis model, doses of 0.1 or 2 Mg/kg were less effective while two doses of 10 Mug/kg 1 h apart were no more effective than the single dose of 10 Ag/kg. The diluent was noninflammatory in both animal models.
Monoclonal antibody IB4 (Merck Sharp and Dohme Research Laboratories), directed against the CD18 epitope of the CDl 1 /CD18 family of leukocyte adhesion molecules, was administered intravenously at 0.5 mg purified protein/kg. TEPC-15 (Hazleton Laboratories, Rockville, MD), a monoclonal antibody recognizing phosphorylcholine, was injected intracisternally or intratracheally at 0.1 mg purified protein/kg.
Rabbit model of meningitis. The rabbit model was performed according to an established protocol (6, 23) . For all experiments, rabbits were challenged in groups of at least four. In brief, 2 kg, specific pathogen-free, New Zealand white rabbits (Hare Marland, Nutley, NJ) were anesthetized with ketamine and xylazine, and a dental acrylic helmet was affixed to the calvarium. 24 h later, the animals were anesthetized with urethane and pentobarbital and placed in a stereotaxic frame. A spinal needle was introduced into the cisterna magna and 300 Ml of cerebrospinal fluid (CSF) was withdrawn. Live bacteria, heat-killed S. pneumoniae R6, pneumococcal cell wall, lipoteichoic acid, or PAF were instilled into the subarachnoid space in 200 Ml of pyrogen-free saline. In some experiments, L-659,989 (10 Mg/kg) was administered intravenously or intracisternally at the same time as the bacterial challenge. Similarly, mAb IB4 (0.5 mg/kg) was administered intravenously at the same time as the bacterial challenge. CSF samples were withdrawn over 6 h and tested for leukocyte density using a counter (Coulter Electronics Inc., Hialeah, FL). The CSF samples were centrifuged at 10,000 g for 5 min, and the supernatant fluid was frozen at -70°C until assayed for protein with the BCA method (Pierce Chemical Co., Rockford, IL). After 6 h, animals were euthanized, and brains were removed immediately for quantitation of brain edema by comparing wet/dry wt (g H20/ 100 g dry wt) (24) .
Rabbit model ofpneumonia. Using a model adapted from that of Onofrio and coworkers ( 13, 25), intratracheal instillation of bacteria or PAF was undertaken in groups ofat least four rabbits. New Zealand white rabbits (2 kg, specific pathogen free; Hare Marland) were anesthetized with ketamine and xylazine and a 2-cm incision was made over the trachea. The catheter from a 19 G 7/8 butterfly infusion set (Abbott Hospitals, Inc., North Chicago, IL) was introduced into the right mainstem bronchus, wedged in place, and then withdrawn 1 cm. The inoculum was introduced into the catheter in 0.2 ml of saline followed by 5 ml ofair, and the incision was stapled. In some animals L-659,989
(10 Mg/kg) or mAb IB4 (0.5 mg/kg) or both were administered intravenously simultaneous with the bacterial challenge. 1 h later in animals challenged with PAF and 3 h later in animals challenged with bacteria, bronchoalveolar lavage (BAL) was performed with saline supplemented with 5% heparin and 0.1% methylene blue (2 x 10 ml). Lavage fluid volume was recorded and the fluid was centrifuged at 1,000 g for 10 min. The pellet was resuspended in 10 ml ofisotonic buffered saline and the number of leukocytes determined using a counter (Coulter Electronics Inc.). The protein content of the supernatant was determined with the BCA method (Pierce Chemical Co.). The protein and leukocyte counts were corrected to reflect values in the original lung fluids by an adaptation (26) of the method of Baughman et al. (27) using the methylene blue as an external marker.
Platelet-activating factor assays. The ability of pneumococcal cell wall to mimic PAF was tested in an assay ofinduction ofaggregation of guinea pig platelets in platelet rich plasma (22, 28) . Cell wall or lipoteichoic acid was tested in two ways: directly for PAF-like effects along-side a PAF control and indirectly for the ability to competitively inhibit PAF-induced effects. Guinea pig (male Dunkin-Hartley, 400-800 g) blood was obtained by heart puncture using a 20 G needle and plastic syringe from animals under light urethane anesthesia. Blood was immediately added to plastic tubes containing 10% (vol/vol) trisodium citrate (0.13 M) and mixed by inversion. After centrifugation of whole blood (1,000 g; 4 min; 20'C), the supernatant platelet-rich plasma (PRP) was aspirated using plastic pipettes and stored in stoppered plastic containers at 370C for the duration of the experiment. Residual blood was centrifuged (8,000 g; 5 min; 20'C) to obtain platelet-poor plasma (PPP). The platelet concentration in PRP was estimated using a cell counter (model ZM; Coulter Electronics) and was adjusted to 4 X 0I cells/ml by addition ofautologous PPP. Platelet aggregation was monitored by standard photometric techniques using a PAP4 Platelet Aggregation Profiler (Bio-Data, Inc., Horsham, PA), where maximum light transmission was set using PPP.
The nied by the rapid appearance ofbrain edema: mean brain wt at Hours 4 h of 409±6 g H20/ 100 g dry wt (upper limit of normal = 400; P < 0.01 ). However, PAF induced only a mild leukocytosis (peak 150 cells/il) (Fig. 2) by 38%±3 also occurred but did not achieve statistical significance.
To determine if PAF-dependent leukocytosis proceeded through the participation of CD18 family of leukocyte adhesion molecules, animals were challenged with PAF in the presence and absence of intravenous anti-CD 18 antibody. All leukocytosis in the CSF was inhibited by CD18 (> 98±6% decrease), while inhibition of leukocytosis in the lung was reduced by half (53±12% decrease). More substantial inhibition of leukocytosis in lung required administration of L-659,989 in combination with the anti-CD18 mAb IB4 (Table II).
Role ofPAF in pneumococcal inflammation. Having demonstrated inflammatory activity of PAF in the subarachnoid space and lung, the contribution of PAF to inflammation during natural bacterial infection was determined. Rabbits were challenged with killed S. pneumoniae intracisternally or intratracheally. Control animals developed a marked leukocytosis and influx of protein in CSF (Fig. 3) . L-659,989 partially suppressed the leukocytosis in CSF (7,168±660 vs 1,523±1,168 mean cells/,gl at 6 h, P < 0.001) and delayed the increase in protein concentration by 2 h. This effect was evident upon challenge with live pneumococcus also, but could not be demonstrated for infection with H. influenzae (Table III) . In the pneumonia model (Table II) , administration of L-659,989 maximally reduced the BAL protein concentration to 43%±3 at 1 h but leukocytosis persisted at > 69%±4 of control levels even at 3 h. Results from both models suggested PAF contributed to leukocyte influx and endothelial permeability during S. pneumoniae infection. However, the greater ability of L-659,989 to prevent leukocytosis in the brain than in the lung, suggested PAF-independent effects were active in lung.
Cross-neutralization of PAF and wall-induced inflammation by antiwall and PAF antagonists. The antiphosphorylcholine mAb TEPC-1 5 binds to the teichoicated components of the pneumococcal cell wall. Administration of the antibody intracisternally neutralized inflammation induced by S. pneumoniae, pneumococcal cell wall, or lipoteichoic acid (Fig. 4) . mAb TEPC-1 5 also reduced brain edema induced by PAF (409±6 vs 393±4 g H20/ 100 g dry wt, P < 0.01) but not the PAF-induced increase in CSF protein concentration (1.6±0.3 vs 1.8±0.4 mg/ml, P > 0.5). Since the antiwall antibody crossneutralized inflammation caused by PAF, we tested the converse, i.e., could L-659,989 neutralize inflammation induced by cell walls. Treatment with L-659,989 decreased CSF leuko- cytosis and protein concentrations induced by pneumococcal cell wall or lipoteichoic acid (Fig. 4) . This cross-neutralization could occur by two mechanisms. In one case, the cell wall or lipoteichoic acid could be acting directly as a PAF analogue, or, in the second case, the wall could generate endogenous PAF. To distinguish these possibilities, cell wall components were tested for the ability to mimic PAF in assays ofplatelet aggregation and neutrophil degranulation in vitro. PAF induced platelet aggregation in a concentration-dependent manner while cell wall and lipoteichoic acid were inactive (Table IV) . Based on these results, 20 ,ug cell wall contains < 1 nM PAF equivalents. Furthermore, neither cell wall derivative inhibited PAF-induced aggregation ofplatelets, in contrast to the effects of L-659,989 (EC50 31 nM). Similar results were obtained using a neutrophil degranulation assay in that neither direct induction ofdegranulation nor inhibition of PAF-induced degranulation could be demonstrated using cell wall or lipoteichoic acid (Table V) .
Discussion
PAF is the first well-characterized phospholipid to be considered a mediator in acute inflammation (30) . PAF is produced by many cells and is rapidly metabolized to the inactive precursor lyso-PAF, suggesting that its biological activities are tightly regulated. PAF acts on a very wide range of cell types (neutrophils, eosinophils, monocytes, muscle cells, fibroblasts, endothelial cells, type II alveolar cells, and neuronal cell lines) and (34) or by PAF, but to reduce only partially the leukocytosis in BAL fluids of rabbits challenged with S. pneumoniae (2, confirmed in this study) or PAF intratracheally. Since the combination of mAb IB4 and L-659,989 greatly inhibited BAL leukocytosis, we suggest that PAF-dependent leukotaxis can occur independent of CD1 8 in the lung; such a CDl 8-independent mechanism has been described for peritoneal inflammation also (35) . In contrast to the lung and peritoneum, PAF appears to induce (36) . To prove the clinical significance of the ability ofPAF to induce protein influx and leukocytosis in lung and brain, a PAF antagonist was administered to animals challenged with pneumococci. The antagonist greatly decreased inflammation in the brain, but only partially reversed inflammation in the lung suggesting that PAF-independent modes of inflammation also contribute to pulmonary inflammation in response to infectious agents. The fact that the PAF-independent pulmonary inflammation was extinguished by addition of the anti-CD 1 8 antibody strengthens the conclusion that PAF and CD 18 work together in brain but independently in lung.
In contrast to inflammation induced by H. influenzae, PAF played a prominent role in pneumococcal disease. PAF is most commonly generated as part of an inflammatory cascade and would be expected to appear after the interaction of pneumococcal cell walls with host receptors. Since the intense inflammatory activity of the pneumococcal cell wall resides in the teichoicated subcomponents and these components share with PAF the requirement for the phosphorylcholine moiety for bioactivity, we investigated: (a) ifthe phosphorylcholine determinants were cross-neutralizing and therefore participated in related biological response pathways; and (b) ifthese wall components might act directly as PAF analogues and exert agonist activity after binding to PAF receptors. No direct PAF-like agonist activity was demonstrable by cell walls for two target cells, platelets and neutrophils. However, two findings in the animal model of meningitis supported cross-neutralization by inhibitory antibodies or drugs. The PAF receptor antagonist neutralized wall-induced inflammation and, conversely, antiwall antibodies neutralized PAF-induced brain edema. Antiwall antibodies are found in sera from patients with pneumococcal pneumonia and a high titer has been associated with a poor clinical outcome (37) . Our findings suggest that antipneumococcal wall antibodies could diminish the effectiveness of PAF during inflammation in the lung and thereby adversely affect the course of disease. We conclude that the intensity of inflammation associated with pneumococcal infection in brain and lung is augmented by a unique participation of endogenous PAF in the inflammatory response to S. pneumoniae cell wall components.
